RNA medicines are at a critical moment in time. mRNA vaccines dominate the headlines in the wake of the COVID-19 pandemic. But huge advances are also being made in RNAi and antisense technologies. Our understanding of RNA chemistry continues to mature. Delivery tools are increasingly sophisticated and impactful. Advances in genomics and gene editing are driving new approaches. And exciting work targeting RNA with small molecules is emerging.
With that in mind, we can’t wait to bring the community together, face-to-face, for the second annual RNA Leaders Europe Congress.
So, if you’re passionate about all things RNA do join us, and more than 600 biotech, pharmaceutical, investment, regulatory and scientific professionals at the RNA Leaders Europe Congress. You’ll hear the latest advances in RNA chemistry, get clinical updates from the companies developing new therapies and source the services partners who are helping to deliver drugs to patients.
"One of the best conferences I have attended."
Dietrich A. Stephan, Ph.D
Chairman, Founder and CEO, Neubase Therapeutics
"It has been really well executed with insightful talks, top-class attendance and remarkable organization."
Director of Clinical Development and Medical Affairs, Medesis Pharma
"Highly relevant talks and panel discussions, and an interesting participant mix of big pharma, biotech, manufacturers and bio investors."
Marie Wikstrom Lindholm
SVP, Head of Molecular Design, Silence Therapeutics
"A fantastic environment in which to discuss the state of the RNA world with the best professionals in its different variants and technologies and to make new professional relationships."
R+D Manager, Sylentis
"Very high quality meeting and extremely valuable networking event with leaders present from across all RNA domains and from Europe and the US. Extremely worthwhile."
Professor of Neuroscience, University of Oxford
500+ companies actively developing RNA therapeutics
4000+ live clinical trials for RNA therapeutics and vaccines
2 major mRNA vaccine approvals in 2020
3 RNAi therapeutic approvals in the past 4 years
1500+ investors actively looking to fund RNA technology
96 successful fund raises by mid 2021 (vs 101 total in 2020)
More than $1.65bn raised by RNA biotech mid 2021
Millions of lives saved by mRNA vaccines to date
Do you offer products or services to support RNA drug development? The pharma and biotech executives attending RNA Leaders World Congress want to meet you! They are looking for: